Aktie A2QK7Q REVIVA PHARMACEUTICALS HOLDINGS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Reviva Pharmaceuticals Holdings, Inc. Nasdaq

Aktien

A2QK7Q

US76152G1004

TZAC

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Riviva Pharmaceuticals Prices $3 Million Offering of Stock, Warrants; Shares Slump
Reviva Pharmaceuticals Holdings, Inc. Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Reviva Pharmaceuticals Holdings, Inc. to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading
Sector Update: Health Care
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall
Reviva Pharmaceuticals to Seek Acquisitions
Reviva Pharmaceuticals Holdings Q3 Loss Widens
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
REVIVA PHARMACEUTICALS HOLDINGS, INC. : HC Wainwright à l'achat
Sector Update: Health Care Stocks Gain Late Afternoon
Sector Update: Health Care
Reviva Shares Surge After Late-Stage Schizophrenia Trial Meets Primary Endpoint
Top Midday Gainers
Reviva Pharmaceuticals Says Phase 3 RECOVER Trial of Brilaroxazine in Adults With Schizophrenia Meets Primary Endpoint
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2QK7Q Aktie
  4. A2QK7Q Aktie
  5. Nachrichten Reviva Pharmaceuticals Holdings, Inc.
  6. Andere Sprachen
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT